Coherus Oncology (CHRS) Return on Sales (2013 - 2026)

Coherus Oncology has disclosed Return on Sales across 14 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.08% (up 6.0% YoY), and the FY2025 annual result was 0.08%, down 1.0% from the prior year.
• Return on Sales came in at 0.0% for Q1 2026 at Coherus Oncology, down from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.74% in Q1 2024 to a low of 0.02% in Q1 2023.
• The 5-year median for Return on Sales is 0.01% (2024), against an average of 0.06%.
• Across the five-year window, Return on Sales soared 76 bps in 2024 and plunged 75 bps in 2025, its largest moves.
• Coherus Oncology's Return on Sales stood at 0.01% in 2022, then surged by 33 bps to 0.01% in 2023, then jumped by 32 bps to 0.01% in 2024, then soared by 215 bps to 0.01% in 2025, then slumped by 117 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.